HRT Benefits and Risks: Is Hormone Therapy Safe? What the Numbers Show
Is HRT safe? The benefits and risks of menopausal hormone therapy in absolute numbers per 1,000 women, from NICE and the WHI trials.

For a generation of women, "HRT" became shorthand for "breast cancer". When part of the Women's Health Initiative (WHI) trial was stopped early in 2002, many women quit treatment overnight. Twenty years of follow-up show a more nuanced picture: for most healthy women who start before 60, the benefits generally outweigh the risks, but those risks are real and depend on the type of HRT, the route and the duration. This guide puts the evidence into absolute numbers.
In short: HRT (menopausal hormone therapy) is the most effective treatment for hot flashes and lowers fracture risk. For healthy women under 60 or within 10 years of menopause, The Menopause Society judges the benefit-risk balance favourable. The main risks are a small, duration-dependent rise in breast cancer with combined HRT (about 20 extra cases per 1,000 women by age 69 after 5 years of use from 50, per NICE) and blood clots with tablets, not with patches or gels. HRT is not used to prevent heart disease or dementia, and there is no fixed time limit: treatment is reviewed yearly.
What HRT is and why it is useful for so many women
HRT replaces the estrogen the ovaries stop making. Women with a uterus also need a progestogen, because estrogen alone thickens the womb lining and raises endometrial cancer risk. NICE recommends combined HRT (estrogen + progestogen) for women with a uterus and estrogen-only HRT after a total hysterectomy. Estrogen can be taken as tablets or through the skin (patches, gels, sprays); low-dose vaginal estrogen treats local symptoms with minimal absorption. The risks below differ by type, so see also our guide to types of HRT: patch, gel or tablets.
Benefits of HRT
Hot flashes and night sweats. The Menopause Society calls hormone therapy the most effective treatment for vasomotor symptoms. A Cochrane review of 24 placebo-controlled trials found oral HRT cut hot flash frequency by about 75% versus placebo and sharply reduced severity. NICE recommends offering HRT for these symptoms. Non-hormonal options are covered in our article on hot flashes and night sweats treatment.
Vaginal dryness and urinary symptoms. NICE recommends offering vaginal estrogen, even alongside systemic HRT, and notes serious side effects are very rare. The Menopause Society says low-dose vaginal estrogen may be used at any age, for as long as needed.
Bones and osteoporosis. Per the NICE discussion aid, of 1,000 women aged 50–54, about 60 not taking HRT have a fragility fracture over 5 years versus 40 on HRT; over 10 years, 127 vs 80 (one observational study). In the WHI randomised trial, combined HRT reduced hip fractures by about a third. Protection fades after stopping.
Other effects. NICE suggests considering HRT for low mood starting around menopause and states it does not raise type 2 diabetes risk.
The WHI story and the "timing hypothesis"
The WHI combined-HRT trial gave 16,608 women aged 50–79 one product (oral conjugated equine estrogens plus medroxyprogesterone acetate) or placebo; the average age across WHI hormone trials was 63. In 2002, after 5.2 years, it was stopped because breast cancers crossed a safety limit. Per 10,000 women per year there were 7 more heart events, 8 more strokes, 8 more pulmonary embolisms and 8 more breast cancers, but 6 fewer colorectal cancers and 5 fewer hip fractures: less than one extra case of each per 1,000 women per year.
Later analyses changed the reading:
- Age matters. Over 13 years, harmful events per 10,000 women per year on combined HRT ranged from 12 extra at ages 50–59 to 38 extra at 70–79. On estrogen-only HRT, women aged 50–59 had 19 fewer events; those aged 70–79 had 51 more.
- No excess deaths. After 18 years, all-cause mortality was 27.1% on hormones vs 27.6% on placebo.
- Timing. The Menopause Society concludes the balance is favourable under 60 or within 10 years of menopause, and less favourable later, because absolute risks of heart disease, stroke, clots and dementia rise.
Caveat: the WHI tested one oral product; today's transdermal estradiol and micronised progesterone have not been tested in trials that large.
HRT and breast cancer: absolute numbers
Women out of 1,000 who develop breast cancer between ages 50 and 69:
| Type of HRT | Never took HRT | 5 years from age 50 | 10 years from age 50 |
|---|---|---|---|
| Combined | 59 | 79 (20 more) | 92 (33 more) |
| Estrogen-only | 59 | 69 (10 more) | 71 (12 more) |
Source: NICE NG23 discussion aid (2024), from national statistics and 24 observational studies.
- Duration counts. Risk with combined HRT rises with length of use, is highest in current users and declines after stopping, but stays slightly raised for at least 10 years (NICE). There was little excess after less than a year of use in a large meta-analysis.
- Regimen. Sequential combined HRT carries less risk than continuous combined, but more than none (NICE). The Collaborative Group estimated one extra breast cancer per 50 users of estrogen plus daily progestogen for 5 years, per 70 with intermittent progestogen and per 200 with estrogen-only HRT. Vaginal estrogen showed no excess.
- Trials vs observational data. In the WHI trial, combined HRT caused about 9 extra breast cancers per 10,000 women per year, while estrogen-only HRT was followed by fewer breast cancers, still visible at 20 years. Observational studies show a small increase instead; NICE summarises estrogen-only as "very little or no increase".
- Progestogen type. NICE found insufficient evidence on whether micronised progesterone or dydrogesterone differ from other progestogens.
HRT and blood clots: tablets vs patches
NICE states that the risk of venous thromboembolism (VTE) rises with oral HRT but not with transdermal HRT, and suggests patches or gels for women at higher risk, including a BMI over 30.
- Trials: the WHI found 8 extra pulmonary embolisms per 10,000 women per year with oral combined HRT; a Cochrane meta-analysis found higher risk even when started before 60 (relative risk 1.74).
- Observational data: a UK study of over 80,000 women with VTE found oral HRT raised the odds by about 58%, while patches and gels showed no increase.
Oral and transdermal HRT have not been compared directly in randomised trials.
HRT, stroke and heart disease
Stroke. About 3 in 1,000 women aged 50–54 have a stroke over 5 years without HRT; with oral estrogen-only HRT, 4 in 1,000; with transdermal HRT, similar to none. NICE says risk with oral estrogen rises with dose, use beyond 5 years and older starting age.
Heart disease. NICE states coronary heart disease risk does not increase with HRT: about 10 vs 9 per 1,000 over 5 years at ages 50–54, a difference compatible with chance. Yet NICE advises not using HRT to prevent heart disease. In women starting after 60 or 10+ years after menopause, trials show no heart effect but more strokes and clots. Our cardiovascular risk calculator estimates your 10-year risk before the appointment.
HRT and dementia
The clearest data come from a randomised trial in women aged 65 or over: combined HRT started at that age roughly doubled dementia risk, 18 vs 9 per 1,000 over 4 years (NICE). Estrogen-only HRT at 65+ showed 19 vs 13 per 1,000 over 5 years, a difference that may be due to chance. For women starting in their 50s, NICE calls the data inconclusive: some observational studies suggest early use may lower risk, others a possible rise in Alzheimer's with more than 5 years of combined HRT. Neither NICE nor The Menopause Society recommends HRT to prevent dementia.
Benefits vs risks of HRT: summary table
| Outcome | Effect (HRT started around 50) | Per 1,000 women | Evidence |
|---|---|---|---|
| Hot flashes | Strong reduction | ~75% fewer vs placebo | RCTs |
| Fragility fractures | Lower | 40 vs 60 over 5 years | Observational + RCT |
| Breast cancer, combined | Higher with duration | 79 vs 59 by 69 | Observational |
| Breast cancer, estrogen-only | Little or none | 69 vs 59 by 69 | Observational (WHI RCT: fewer) |
| Endometrial cancer | Lower with continuous combined | 1 vs 4 over 5 years | Observational |
| Ovarian cancer | Very slightly higher | 2 vs 1 over 5 years | Observational |
| Blood clots | Higher with tablets only | 0.8 extra per year (WHI, oral) | RCT + observational |
| Stroke | Slightly higher with tablets | 4 vs 3 over 5 years | RCT + observational |
| Heart disease | No increase | 10 vs 9 over 5 years | RCT |
| Dementia (started 65+) | Higher with combined | 18 vs 9 over 4 years | RCT |
Sources: NICE NG23 and discussion aid; WHI publications; The Menopause Society 2022.
Who should not take HRT
The Menopause Society lists these contraindications:
- unexplained vaginal bleeding;
- liver disease;
- previous estrogen-sensitive cancer, including breast cancer;
- previous heart attack, coronary heart disease, stroke or blood clots;
- inherited or personal high risk of thrombosis.
The NHS adds untreated high blood pressure, a history of ovarian or womb cancer, and pregnancy. Not all are absolute: NICE favours transdermal HRT for women at higher clot risk and says women with past heart disease or stroke can discuss HRT with a menopause specialist. HRT is not a contraceptive.
How long can you take HRT? HRT after 60
- No arbitrary limit. NICE recommends the lowest effective dose, a review at 3 months, then yearly. The Menopause Society says HRT does not need to be routinely stopped at 60 or 65; continuing for persistent symptoms is reasonable, with reassessment and possibly a lower dose or transdermal route.
- Starting after 60 or 10+ years after menopause needs careful individual assessment.
- Stopping. Tapering may limit short-term symptom return, but long-term outcomes are the same (NICE). About half of women get hot flashes again, and bone protection is lost.
- Early menopause. Before 40, hormones are advised at least until the usual age of menopause. See menopause symptoms, age and diagnosis and perimenopause symptoms.
HRT myths vs facts
| Myth | Fact |
|---|---|
| "HRT gives most women breast cancer." | Combined HRT adds about 20 cases per 1,000 by 69 after 5 years; estrogen-only adds little or none. |
| "All HRT carries the same clot risk." | Tablets raise it; patches and gels did not in large studies. |
| "You must stop at 5 years or at 60." | No fixed limit; the decision is reviewed yearly. |
| "HRT causes heart attacks." | No increase in coronary heart disease per NICE, but it is not for prevention. |
| "Compounded bioidentical hormones are safer." | The Menopause Society cites lack of safety data and minimal regulation. |
Tracking symptoms when you start or change HRT
A symptom record alongside each patch, gel or dose change helps at the 3-month review. One option is Amelie (partner app, iPhone): it logs hot flashes, night sweats, sleep, mood, energy, brain fog, joint pain and your own symptoms, and shows them week by week since each HRT change so you can compare treatment periods. It covers all treatment types, from patches and pills to vaginal estrogen, IUDs, testosterone and non-hormonal options, sends reminders that don't name the medicine on the lock screen, tracks mammograms, Pap/HPV tests and bone density scans, and makes a one-page PDF for your appointment. Data stays on the phone, no account; 18 languages; 1-week free trial, then subscription. Amelie does not diagnose, predict periods, judge lab values or suggest doses. You can read more about this HRT tracker app on amelie.health.
Conclusion
HRT is neither a miracle nor a poison. It is the most effective treatment for hot flashes, treats vaginal symptoms and protects bones, and for healthy women under 60 the balance is generally favourable. The risks (breast cancer with combined HRT, clots and stroke with tablets) are small in absolute terms but real, so the choice of type, route and duration is made with your doctor and reviewed yearly.
Frequently asked questions
Is HRT safe? For healthy women under 60 or within 10 years of menopause without contraindications, The Menopause Society considers the benefits greater than the risks. Safety depends on the type, route, duration and your personal risk factors.
How much does HRT increase breast cancer risk? According to NICE, 5 years of combined HRT from age 50 means about 79 instead of 59 breast cancers per 1,000 women by age 69. With estrogen-only HRT the figure is 69, and the WHI trial even found fewer cases.
Do HRT patches cause blood clots? NICE states that patches, gels and sprays do not increase clot risk, while tablets do. That is why transdermal HRT is preferred for women at higher risk, including those with a BMI over 30.
Can you take HRT after 60? Continuing after 60 or 65 is possible for persistent symptoms, with regular review. Starting for the first time after 60 carries higher risks and needs individual assessment.
How long can you take HRT? There is no fixed limit. NICE recommends a review at 3 months and then yearly, at the lowest effective dose.
Who should not take HRT? HRT is generally not recommended with unexplained vaginal bleeding, liver disease, previous breast or other estrogen-sensitive cancer, or a history of heart attack, stroke or blood clots; some cases can be discussed with a specialist.
Does HRT cause heart disease or dementia? NICE found no increase in coronary heart disease, but HRT is not recommended for prevention. Dementia risk rose when combined HRT was started at 65 or over; for women starting in their 50s the data are inconclusive.
Does HRT help with osteoporosis? Yes, while it is taken: about 40 instead of 60 fragility fractures per 1,000 women over 5 years from age 50, per NICE data. The protection fades after stopping.
Read next
- Perimenopause symptoms: at what age it starts and how long it lasts
- Menopause symptoms, average age and how it is diagnosed
- Types of HRT compared: patch, gel or tablets
- Hot flashes and night sweats: hormonal and non-hormonal treatment
Useful tools
- Cardiovascular risk calculator (SCORE2): estimate your 10-year heart and stroke risk before discussing HRT.
- BMI calculator: a BMI over 30 is one reason NICE suggests patches or gels over tablets.
- BMR calculator: estimate your calorie needs as metabolism changes around menopause.
Sources
- NICE. Menopause: identification and management (NG23), Recommendations. 2015, updated 2024–2026. https://www.nice.org.uk/guidance/ng23/chapter/Recommendations
- NICE. HRT and the likelihood of some medical conditions: a discussion aid (NG23). 2024. https://www.nice.org.uk/guidance/ng23/resources/incidence-of-medical-conditions-with-and-without-hrt-a-discussion-aid-pdf-13553199901
- The North American Menopause Society. The 2022 hormone therapy position statement. Menopause. 2022;29(7):767–794. https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf
- Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the WHI randomized controlled trial. JAMA. 2002. https://pubmed.ncbi.nlm.nih.gov/12117397/
- Manson JE, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the WHI randomized trials. JAMA. 2013. https://pubmed.ncbi.nlm.nih.gov/24084921/
- Manson JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the WHI randomized trials. JAMA. 2017. https://pubmed.ncbi.nlm.nih.gov/28898378/
- Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk. Lancet. 2019. https://pubmed.ncbi.nlm.nih.gov/31474332/
- Vinogradova Y, et al. Use of hormone replacement therapy and risk of venous thromboembolism. BMJ. 2019. https://pubmed.ncbi.nlm.nih.gov/30626577/
- MacLennan AH, et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004. https://pubmed.ncbi.nlm.nih.gov/15495039/
- NHS. Benefits and risks of hormone replacement therapy (HRT). 2023. https://www.nhs.uk/medicines/hormone-replacement-therapy-hrt/benefits-and-risks-of-hormone-replacement-therapy-hrt/
- NHS. About hormone replacement therapy (HRT). 2023. https://www.nhs.uk/medicines/hormone-replacement-therapy-hrt/about-hormone-replacement-therapy-hrt/
Informational material, updated November 2026. It does not replace advice from your doctor.
This article is for general information only and does not replace advice from your doctor or pharmacist. Do not start, stop or change a treatment without medical supervision.


